GlassScriptPhysician profile
Dina K Kiseleva
NPI 1871785501
$6,576.02
in general payments reported to CMS, 2019-2025
43 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $442 · 2021: $864 · 2022: $881 · 2023: $983 · 2024: $747 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.63 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $596.45 | 2022-2025 | |
| Amgen INC. | $532.19 | 2019-2025 | Evenity, Prolia |
| Agile Therapeutics, INC. | $365.31 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $300.46 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $274.56 | 2020-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $267.66 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Novo Nordisk INC | $242.63 | 2023-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $236.52 | 2019-2025 | |
| Therapeuticsmd, INC. | $224.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $211.71 | 2019-2024 | Gardasil 9, Gardasil |
| Allergan, INC. | $196.91 | 2019-2020 | |
| Hologic Sales and Service, LLC | $174.20 | 2019-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Baxter Healthcare | $163.67 | 2022-2025 | Perclot, Floseal |
| Pfizer INC. | $163.09 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $141.28 | 2025 | Zurzuvae |
| Lupin INC. | $116.32 | 2019-2020 | |
| Astellas Pharma US INC | $105.84 | 2023-2025 | Veozah |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Medtronic, INC. | $101.29 | 2025 | Sonicision |
| Daiichi Sankyo INC. | $74.40 | 2021-2022 | |
| Myovant Sciences INC. | $66.54 | 2021-2022 | |
| Lilly USA, LLC | $61.68 | 2025 | Zepbound, Mounjaro |
| Convatec INC. | $60.60 | 2019 | |
| Nevro Corp. | $59.40 | 2019 | |
| Sumitomo Pharma America, INC. | $45.33 | 2025 | Myfembree |
| Aspira Women'S Health INC | $41.99 | 2022-2023 | Ova1 |
| Supernus Pharmaceuticals, INC. | $41.85 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $39.34 | 2019 | |
| Amag Pharmaceuticals, INC. | $38.65 | 2019 | |
| Exact Sciences Corporation | $37.69 | 2024 | Cologuard Collection Kit |
| Ascend Therapeutics US, LLC | $36.40 | 2023-2024 | |
| Abbott Laboratories | $34.83 | 2023 | Proclaim, Eterna |
| Seqirus USA INC | $33.51 | 2023 | Flucelvax Quadrivalent |
| Vertex Pharmaceuticals Incorporated | $33.46 | 2025 | |
| Becton, Dickinson and Company | $33.14 | 2022-2024 | Bd Max System, Bd Max Instrument |
| Scynexis, INC. | $31.45 | 2022 | |
| Duchesnay USA Incorporated | $22.08 | 2019 | |
| Millicent US INC | $21.06 | 2025 | Femlyv, Intrarosa |
| Neuronetics, INC. | $17.65 | 2023 | Neurostar Tms Therapy System |
| Roche Diagnostics Corporation | $17.53 | 2020 | |
| Organon LLC | $15.27 | 2024 | |
| Shield Therapeutics INC | $15.25 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Kiseleva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.